GICS Sector : Healthcare
Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide.The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM).It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures.
Apyx Medical reported total revenue of $12.9 million for Q3 2025, a 12% increase from $11.5 million in Q3 2024, driven primarily by the Surgical Aesthetics segment, which saw a 19% increase to $11.1 million. The gross profit margin expanded to 64.4% from 60.5% in Q3 2024, indicating effective cost management and pricing power. Operating expenses decreased to $9.1 million from $10.6 million, further highlighting the company's ability to manage its resources efficiently. The net loss was $2 million, or $0.05 per share, an improvement over the loss per share of $0.07 in Q3 2024. Adjusted EBITDA loss was $0.1 million. The actual EPS of -$0.05 beat estimates of -$0.06, showcasing a better-than-expected performance.
Publication Date: Nov -26
The Surgical Aesthetics segment, formerly known as the Advanced Energy segment, saw significant growth due to sales of the AYON Body Contouring System and single-use handpieces. The company has rebranded this segment to reflect its focus on innovative aesthetic products. Apyx Medical updated its 2025 revenue guidance to $50.5 million to $52.5 million, with the Surgical Aesthetics segment expected to contribute $43 million to $45 million. The successful launch of the AYON system, with its strong market feedback and initial sales, is a key driver of this growth. The company expects to receive FDA clearance for power liposuction on AYON in Q1 2026, further enhancing the system's capabilities.
Apyx Medical believes that the market has been disrupted by GLP-1 drugs, creating a high demand for technologies addressing skin laxity and body contouring. A McKinsey study found that 63% of patients on GLP-1 drugs are new to aesthetics, a trend the company expects to continue over the next decade. Currently focused on the US market, Apyx Medical plans to expand internationally, targeting Europe, the Middle East, Brazil, and Latin America, pending necessary registrations.
Analysts estimate next year's revenue growth at 6.6%. With a P/S Ratio of 3.19 and an EV/EBITDA of -15.02, the market is pricing in significant growth expectations. The ROE of -153.77% and ROIC of -20.69% indicate that the company is currently not generating returns on its investments, but the growth in the Surgical Aesthetics segment and the potential for international expansion could improve these metrics in the future.
Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
Dec -03
Apyx Medical Corporation Announces Pricing of $10 Million Public Offering of Common Stock
Nov -18
Apyx Medical Corporation Announces Proposed Public Offering of Common Stock
Nov -17
Apyx Medical Corporation (APYX) Q3 2025 Earnings Call Transcript
Nov -06
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Oct -23
Apyx Medical (NASDAQ:APYX) Stock Price Up 7.2% – Should You Buy?
Oct -21
Apyx Medical Corporation - Special Call
Oct -14
Apyx Medical Corporation (APYX) Q2 2025 Earnings Call Transcript
Aug -08
Apyx Medical Corporation's Advanced Energy segment growth is driven by increasing adoption of minimally invasive procedures, rising demand for electrosurgical devices, and expanding applications in laparoscopic and endoscopic surgeries. Additionally, strategic partnerships, product innovations, and geographic expansion contribute to the 12% growth rate.
Apyx Medical Corporation's 14% growth in Original Equipment Manufacturing is driven by increasing demand for electrosurgical devices, expansion into new markets, and strategic partnerships. Additionally, advancements in technology, such as the development of innovative products like the Renuvion system, have contributed to the company's growth.
Apyx Medical's Renuvion is a helium plasma technology used for precision cutting, coagulation, and ablation of soft tissue in medical procedures.
Apyx Medical's J-Plasma is a helium plasma technology used for precise dissection, coagulation, and ablation of soft tissue in surgical procedures.
Apyx Medical's Renuvion Dermal Handpiece is a helium plasma technology used for skin resurfacing and rejuvenation.
Apyx Medical's Renuvion APS is an advanced plasma system used for precision cutting, coagulation, and ablation of soft tissue in medical procedures.
Apyx Medical Corporation operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the evolving nature of the medical device industry.
Apyx Medical Corporation's customers are primarily hospitals and medical facilities, which have limited bargaining power due to the specialized nature of the company's products.
Apyx Medical Corporation relies on a few key suppliers for critical components, which gives them some bargaining power, but the company's strong relationships and diversified supply chain mitigate this risk.
The medical device industry has high barriers to entry, including regulatory hurdles and significant capital requirements, which limits the threat of new entrants.
Apyx Medical Corporation operates in a competitive market with several established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 55.69% |
| Debt Cost | 7.27% |
| Equity Weight | 44.31% |
| Equity Cost | 9.42% |
| WACC | 8.22% |
| Leverage | 125.66% |
Value: 6.8
Growth: 7.4
Quality: 4.0
Yield: 0.0
Momentum: 9.0
Volatility: 0.7
1-Year Total Return ->
Value: 7.4
Growth: 3.3
Quality: 4.6
Yield: 0.0
Momentum: 8.0
Volatility: 3.0
1-Year Total Return ->
Value: 8.0
Growth: 6.4
Quality: 3.7
Yield: 0.0
Momentum: 4.0
Volatility: 3.7
1-Year Total Return ->
Value: 6.8
Growth: 2.9
Quality: 3.6
Yield: 0.0
Momentum: 9.5
Volatility: 0.7
1-Year Total Return ->
Value: 7.6
Growth: 4.7
Quality: 3.9
Yield: 0.0
Momentum: 3.0
Volatility: 1.0
1-Year Total Return ->
Value: 10.0
Growth: 1.6
Quality: 5.2
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->